A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
NCT00539383
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors With and Without Brain Metastases
Interventions
DRUG:
ANG1005
Sponsor
Angiochem Inc